Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Merck & Company (MRK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 148,127,792
  • Shares Outstanding, K 2,724,440
  • Annual Sales, $ 39,807 M
  • Annual Income, $ 3,920 M
  • 36-Month Beta 0.78
  • Price/Sales 3.71
  • Price/Cash Flow 9.36
  • Price/Book 3.86

Price Performance

See More
Period Period Low Period High Performance
1-Month
53.63 +1.34%
on 11/20/17
63.13 -13.90%
on 10/25/17
-8.76 (-13.88%)
since 10/24/17
3-Month
53.63 +1.34%
on 11/20/17
66.41 -18.16%
on 09/18/17
-8.36 (-13.33%)
since 08/24/17
52-Week
53.63 +1.34%
on 11/20/17
66.80 -18.64%
on 03/01/17
-7.29 (-11.83%)
since 11/23/16

Most Recent Stories

More News
Nektar (NKTR) Stock Up More than 300% This Year: Here's Why

Nektar's (NKTR) shares skyrocket in the year so far on a robust pipeline including several study initiations and strategic collaborations.

AZN : 33.84 (+0.03%)
MRK : 54.35 (-0.04%)
AMGN : 170.12 (+0.09%)
NKTR : 52.59 (+5.71%)
J&J & Glaxo's Jucala Approval Puts Spotlight on HIV Space

As HIV and AIDS have limited medical cure but huge medical need, we see how different companies are trying to tap into this huge market.

MYL : 37.37 (+0.24%)
JNJ : 138.01 (+0.52%)
MRK : 54.35 (-0.04%)
ABBV : 94.72 (+0.26%)
GILD : 72.46 (-0.49%)
GSK : 35.04 (-0.06%)
Cancer Space Update: 2 Drugs Receive Regulatory Nod in EU

This week the European Commission granted approval to Zejula for ovarian cancer and for label expansion of Tasigna in first-line Ph+ chronic myeloid leukemia.

CLDX : 2.90 (+0.35%)
AZN : 33.84 (+0.03%)
JNJ : 138.01 (+0.52%)
MRK : 54.35 (-0.04%)
LLY : 84.03 (+0.42%)
NVS : 85.08 (+0.71%)
RHHBY : 31.6000 (-0.19%)
Here's Why Merck Stock Is Down in 2017 Despite a Rising Industry

Shares of Merck (MRK) have declined so far this year compared to an increase witnessed by the industry due to some notable pipeline setbacks.

AZN : 33.84 (+0.03%)
JNJ : 138.01 (+0.52%)
MRK : 54.35 (-0.04%)
LLY : 84.03 (+0.42%)
3 Companies Competing to Gain Lead in Ovarian Cancer Market

Three companies including a major pharma player are developing drugs for the treatment of ovarian cancer using a new technology instead of chemotherapy and competing to gain market share.

AZN : 33.84 (+0.03%)
MRK : 54.35 (-0.04%)
CLVS : 60.94 (-0.94%)
ABBV : 94.72 (+0.26%)
TSRO : 83.41 (-0.60%)
PFE : 35.49 (+0.17%)
BMY : 61.43 (+0.47%)
Pharma Stock Roundup: FDA Approves J&J, Glaxo HIV Drug, Roche Presents Data

Key highlights this week include the FDA approval of GlaxoSmithKline (GSK) and J&J's new HIV drug and study data from Roche.

AZN : 33.84 (+0.03%)
JNJ : 138.01 (+0.52%)
MRK : 54.35 (-0.04%)
NVS : 85.08 (+0.71%)
RHHBY : 31.6000 (-0.19%)
GSK : 35.04 (-0.06%)
BMY : 61.43 (+0.47%)
Today's Research Reports on Stocks to Watch: Ampio Pharmaceuticals and Agenus Inc.

NEW YORK, NY / ACCESSWIRE / November 24, 2017 / Shares of Ampio blew up on Wednesday after encouraging data was published in a peer review journal about its Ampion serum that is being developed to treat...

AGEN : 3.92 (-2.49%)
MRK : 54.35 (-0.04%)
AMPE : 1.99 (+13.71%)
TESARO (TSRO) Ovarian Cancer Drug Zejula Gets Approval in EU

TESARO (TSRO) received a boost with the approval of Zejula in Europe for ovarian cancer, following its approval in the United States earlier this year.

AZN : 33.84 (+0.03%)
MRK : 54.35 (-0.04%)
CLVS : 60.94 (-0.94%)
TSRO : 83.41 (-0.60%)
Global 9-decanoic Acid Methyl Ester Market 2017-2021 - Key Vendors are Elevance Renewable Sciences, J&K Scientific, Matreya, Merck & P&G Chemicals - Research and Markets

The "Global 9-decanoic Acid Methyl Ester Market 2017-2021" report has been added to Research and Markets' offering.

MRK : 54.35 (-0.04%)
Asian shares advance as Wall Street regains ground

TOKYO (AP) — Asian shares edged mostly higher Tuesday after Wall Street regained lost ground overnight amid subdued trading ahead of the Thanksgiving holiday.

ZION : 46.35 (unch)
TWX : 89.50 (-0.57%)
IHICY : 7.8500 (+1.42%)
MRK : 54.35 (-0.04%)
BBY : 57.00 (+0.90%)
AGN : 173.53 (-0.74%)
MRO : 15.13 (+1.68%)
HD : 172.33 (+0.16%)
MMM : 231.38 (-0.09%)
GE : 18.19 (+0.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The company devotes extensive efforts to increase access to medicines...

See More

Key Turning Points

2nd Resistance Point 54.88
1st Resistance Point 54.62
Last Price 54.35
1st Support Level 54.10
2nd Support Level 53.84

See More

52-Week High 66.80
Fibonacci 61.8% 61.77
Fibonacci 50% 60.22
Fibonacci 38.2% 58.66
Last Price 54.35
52-Week Low 53.63

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart